Stockscreener 앱 받기
1.2885
1.63%
-0.0214
전일 마감가:
$1.3099
열려 있는:
$1.32
하루 거래량:
4,191
Relative Volume:
0.12
시가총액:
$6.69M
수익:
$93.76M
순이익/손실:
$-13.68M
주가수익비율:
-0.4899
EPS:
-2.63
순현금흐름:
$8.77M
1주 성능:
+18.76%
1개월 성능:
+25.10%
6개월 성능:
-30.35%
1년 성능:
-57.19%
1일 변동 폭
$1.23
$1.3675
1주일 범위
$1.06
$1.47
52주 변동 폭
$0.95
$3.4475
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
AYTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
1.2885 | 6.69M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
157.47 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.35 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.61 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.44 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
296.16 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire
Aytu BioPharma at Planet MicroCap: Strategic Realignment and Growth By Investing.com - Investing.com Canada
Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 | AYTU Stock News - GuruFocus
Aytu BioPharma CEO Reveals Growth Strategy at Exclusive Vegas Investor Showcase - Stock Titan
Aytu BioPharma, Inc. (NASDAQ:AYTU) On The Verge Of Breaking Even - simplywall.st
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director - ACCESS Newswire
AYTU stock touches 52-week low at $1.13 amid market challenges - Investing.com India
Vascular Ehlers-Danlos Syndrome Market Growth Projections - openPR.com
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer - ACCESS Newswire
AYTU stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
AYTU BIOSCIENCE, INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com Australia
Insider Buying: Joshua Disbrow Acquires 15,000 Shares of Aytu Bi - GuruFocus.com
Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock - Investing.com India
Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock By Investing.com - Investing.com South Africa
AYTU BIOPHARMA CEO Acquires 15,000 Shares - TradingView
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 - ACCESS Newswire
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance - ACCESS Newswire
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue - ACCESS Newswire
Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN
AYTU stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia
AYTU stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 - ACCESS Newswire
Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings - MSN
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row - ACCESS Newswire
Aytu BioPharma’s Imminent Breakthrough: Can It Reach Profitability? - Mi Valle
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance
Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Stro - GuruFocus.com
Aytu BioScience Earnings Call: Growth Amid Challenges - TipRanks
Denver biotech cuts $500K check when it parted ways with its CFO - The Business Journals
Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... By GuruFocus - Investing.com Canada
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Reports Strong Q2 Earnings Growth - TipRanks
Aytu BioPharma Inc. (AYTU) reports earnings - Quartz
AYTU BIOPHARMA, INC SEC 10-Q Report - TradingView
Aytu BioPharma Reports Fiscal 2025 Second Quarter Results - TradingView
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results - ACCESS Newswire
Aytu BioPharma Turns Profitable: Key Portfolio Growth Drives Q2 Transformation - StockTitan
Aytu BioPharma Reports First Quarter 2022 Financial Results - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 - Galveston County Daily News
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.87%
자본화:
|
볼륨(24시간):